Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials
出版年份 2020 全文链接
标题
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials
作者
关键词
Cancer treatment, Quality of life, Systematic reviews, Database searching, Cancer immunotherapy, Clinical trials (cancer treatment), Clinical trials, Randomized controlled trials
出版物
PLoS One
Volume 15, Issue 1, Pages e0227344
出版商
Public Library of Science (PLoS)
发表日期
2020-01-25
DOI
10.1371/journal.pone.0227344
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non–Small-cell Lung Cancer
- (2018) Rodolfo Bordoni et al. Clinical Lung Cancer
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study
- (2018) Martin Reck et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-Related Quality of Life in Cancer Patients Treated with PD-(L)1 Inhibitors: A Systematic Review
- (2018) Omar Abdel-Rahman et al. Expert Review of Anticancer Therapy
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
- (2017) Teresa M. Petrella et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life results from the phase III CheckMate 067 study
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
- (2017) Leisha A. Emens et al. EUROPEAN JOURNAL OF CANCER
- A systematic review of the quality of statistical methods employed for analysing quality of life data in cancer randomised controlled trials
- (2017) Jean-Francois Hamel et al. EUROPEAN JOURNAL OF CANCER
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
- (2017) Corneel Coens et al. LANCET ONCOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
- (2017) Julie R Brahmer et al. LANCET ONCOLOGY
- Quality of life after nivolumab treatment for head and neck cancer
- (2017) Susanne Singer LANCET ONCOLOGY
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study
- (2016) G. V. Long et al. ANNALS OF ONCOLOGY
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
- (2016) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
- (2016) David Cella et al. LANCET ONCOLOGY
- Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials
- (2016) Irina Ghislain et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Illness representations, coping, and illness outcomes in people with cancer: a systematic review and meta-analysis
- (2016) Emma M. Richardson et al. PSYCHO-ONCOLOGY
- Reporting and dealing with missing quality of life data in RCTs: has the picture changed in the last decade?
- (2016) S. Fielding et al. QUALITY OF LIFE RESEARCH
- Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials
- (2015) Fabio Efficace et al. CANCER
- Health-Related Quality of Life After Colorectal Cancer in England: A Patient-Reported Outcomes Study of Individuals 12 to 36 Months After Diagnosis
- (2015) Amy Downing et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using a personalized measure (Patient Generated Index (PGI)) to identify what matters to people with cancer
- (2015) Ala’ S. Aburub et al. SUPPORTIVE CARE IN CANCER
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
- (2014) D. Schadendorf et al. ANNALS OF ONCOLOGY
- Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials
- (2014) Efstathios Zikos et al. LANCET ONCOLOGY
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
- (2012) Dennis A Revicki et al. Health and Quality of Life Outcomes
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials
- (2010) John T. Maringwa et al. SUPPORTIVE CARE IN CANCER
- Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG
- (2010) Heather-Jane Au et al. Expert Review of Pharmacoeconomics & Outcomes Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now